Matches in SemOpenAlex for { <https://semopenalex.org/work/W1907250075> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W1907250075 endingPage "1918" @default.
- W1907250075 startingPage "1914" @default.
- W1907250075 abstract "PURPOSE A phase II trial that used fluorouracil (5-FU) and chlorozotocin (CTZ) was performed in patients with metastatic islet cell carcinoma to determine the response rate and toxicity. PATIENTS AND METHODS Patients received four cycles of induction chemotherapy. Good-risk patients received 5-FU 800 mg/m2/d days 1 to 4 as a continuous intravenous (IV) infusion (CIV) and CTZ 175 mg/m2 IV on day 1. Poor-risk patients (previous radiation to > or = 25% bone marrow-bearing areas; serum bilirubin > or = 5 mg/dL; creatinine > 1.0 mg/dL) received 5-FU 600 mg/m2/d and CTZ 75 mg/m2 in a similar manner. In responding or stable patients, reduced doses of 5-FU and CTZ were continued as maintenance therapy (maximum, 18 months). RESULTS Forty-seven of 51 patients were eligible, and 44 received chemotherapy. Fourteen of 44 patients had partial responses, with 13 of 36 (36%; 95% confidence interval [CI], 21.0% to 54.0%) good-risk patients and one of eight (12%; 95% CI, 0.3 to 52.6%) poor-risk patients responding. Median survival of all patients was 25 months, and the median response duration was 11 months. Side effects were moderate to severe and included myelosuppression and gastrointestinal toxicity. Thirteen patients developed renal toxicity, which was severe or life-threatening in five. This seemed to be related to the administration of cumulative doses of CTZ > or = 1,500 mg. CONCLUSION These results demonstrate that the combination of 5-FU and CTZ has activity in islet cell carcinoma, but the occurrence of renal toxicity secondary to CTZ may limit the use of this agent." @default.
- W1907250075 created "2016-06-24" @default.
- W1907250075 creator A5004963523 @default.
- W1907250075 creator A5021725237 @default.
- W1907250075 creator A5042336765 @default.
- W1907250075 creator A5054034686 @default.
- W1907250075 creator A5061209297 @default.
- W1907250075 creator A5082466279 @default.
- W1907250075 creator A5089221698 @default.
- W1907250075 date "1992-12-01" @default.
- W1907250075 modified "2023-10-17" @default.
- W1907250075 title "Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study." @default.
- W1907250075 cites W1967612457 @default.
- W1907250075 cites W2018834441 @default.
- W1907250075 cites W2021387542 @default.
- W1907250075 cites W2069087191 @default.
- W1907250075 cites W2319339650 @default.
- W1907250075 cites W2339290868 @default.
- W1907250075 cites W2340185896 @default.
- W1907250075 cites W2383461052 @default.
- W1907250075 cites W2414496343 @default.
- W1907250075 doi "https://doi.org/10.1200/jco.1992.10.12.1914" @default.
- W1907250075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1333517" @default.
- W1907250075 hasPublicationYear "1992" @default.
- W1907250075 type Work @default.
- W1907250075 sameAs 1907250075 @default.
- W1907250075 citedByCount "33" @default.
- W1907250075 countsByYear W19072500752012 @default.
- W1907250075 countsByYear W19072500752014 @default.
- W1907250075 countsByYear W19072500752015 @default.
- W1907250075 crossrefType "journal-article" @default.
- W1907250075 hasAuthorship W1907250075A5004963523 @default.
- W1907250075 hasAuthorship W1907250075A5021725237 @default.
- W1907250075 hasAuthorship W1907250075A5042336765 @default.
- W1907250075 hasAuthorship W1907250075A5054034686 @default.
- W1907250075 hasAuthorship W1907250075A5061209297 @default.
- W1907250075 hasAuthorship W1907250075A5082466279 @default.
- W1907250075 hasAuthorship W1907250075A5089221698 @default.
- W1907250075 hasConcept C126322002 @default.
- W1907250075 hasConcept C141071460 @default.
- W1907250075 hasConcept C2776581026 @default.
- W1907250075 hasConcept C2776694085 @default.
- W1907250075 hasConcept C2777472916 @default.
- W1907250075 hasConcept C2778496288 @default.
- W1907250075 hasConcept C2780456651 @default.
- W1907250075 hasConcept C29730261 @default.
- W1907250075 hasConcept C44249647 @default.
- W1907250075 hasConcept C71924100 @default.
- W1907250075 hasConcept C90924648 @default.
- W1907250075 hasConceptScore W1907250075C126322002 @default.
- W1907250075 hasConceptScore W1907250075C141071460 @default.
- W1907250075 hasConceptScore W1907250075C2776581026 @default.
- W1907250075 hasConceptScore W1907250075C2776694085 @default.
- W1907250075 hasConceptScore W1907250075C2777472916 @default.
- W1907250075 hasConceptScore W1907250075C2778496288 @default.
- W1907250075 hasConceptScore W1907250075C2780456651 @default.
- W1907250075 hasConceptScore W1907250075C29730261 @default.
- W1907250075 hasConceptScore W1907250075C44249647 @default.
- W1907250075 hasConceptScore W1907250075C71924100 @default.
- W1907250075 hasConceptScore W1907250075C90924648 @default.
- W1907250075 hasIssue "12" @default.
- W1907250075 hasLocation W19072500751 @default.
- W1907250075 hasLocation W19072500752 @default.
- W1907250075 hasOpenAccess W1907250075 @default.
- W1907250075 hasPrimaryLocation W19072500751 @default.
- W1907250075 hasRelatedWork W1863321637 @default.
- W1907250075 hasRelatedWork W1882659763 @default.
- W1907250075 hasRelatedWork W1990145767 @default.
- W1907250075 hasRelatedWork W2037099262 @default.
- W1907250075 hasRelatedWork W2252704667 @default.
- W1907250075 hasRelatedWork W2323674418 @default.
- W1907250075 hasRelatedWork W2365983310 @default.
- W1907250075 hasRelatedWork W2372729059 @default.
- W1907250075 hasRelatedWork W2411350370 @default.
- W1907250075 hasRelatedWork W78462481 @default.
- W1907250075 hasVolume "10" @default.
- W1907250075 isParatext "false" @default.
- W1907250075 isRetracted "false" @default.
- W1907250075 magId "1907250075" @default.
- W1907250075 workType "article" @default.